# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $48 price target.
Truist Securities analyst Robyn Karnauskas reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $74 price target.
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-th...
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market o...
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.